Sanofi (NASDAQ:SNY) Shares Sold by Invesco Ltd.

Key Points

• Invesco Ltd. reduced its position in Sanofi shares by 1.7% during Q1, selling 199,738 shares and now owning approximately 0.47% of the company, valued at around $657.7 million.
• Sanofi reported $0.90 earnings per share for the most recent quarter, missing estimates, while revenue was $11.34 billion, significantly higher than expectations.
• Equities analysts are generally optimistic about Sanofi, with a current average rating of "Buy" and a consensus target price of $62.00 from various research reports.

Invesco Ltd. reduced its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 1.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,859,545 shares of the company's stock after selling 199,738 shares during the period. Invesco Ltd. owned about 0.47% of Sanofi worth $657,730,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Accent Capital Management LLC acquired a new stake in shares of Sanofi during the first quarter valued at about $29,000. Eastern Bank grew its stake in Sanofi by 121.0% during the 1st quarter. Eastern Bank now owns 548 shares of the company's stock valued at $30,000 after purchasing an additional 300 shares in the last quarter. Bessemer Group Inc. increased its holdings in Sanofi by 59.8% during the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company's stock worth $32,000 after purchasing an additional 242 shares during the last quarter. Golden State Wealth Management LLC raised its position in shares of Sanofi by 619.3% in the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock valued at $35,000 after purchasing an additional 545 shares in the last quarter. Finally, Brentview Investment Management LLC purchased a new position in shares of Sanofi during the 1st quarter valued at approximately $42,000. 14.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Trading Down 0.6%

Shares of SNY stock opened at $47.16 on Friday. Sanofi has a 12 month low of $44.73 and a 12 month high of $60.12. The company has a market cap of $115.79 billion, a PE ratio of 11.34, a price-to-earnings-growth ratio of 1.13 and a beta of 0.48. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. The business's 50 day moving average is $48.67 and its two-hundred day moving average is $51.97.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The business had revenue of $11.34 billion for the quarter, compared to the consensus estimate of $9.91 billion. During the same quarter in the previous year, the company earned $1.73 EPS. Sanofi's revenue for the quarter was down 7.0% compared to the same quarter last year. Equities analysts predict that Sanofi will post 4.36 EPS for the current year.

Analyst Ratings Changes

SNY has been the subject of a number of research reports. BNP Paribas initiated coverage on Sanofi in a research note on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price target for the company. Wall Street Zen upgraded Sanofi from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Guggenheim reiterated a "buy" rating on shares of Sanofi in a report on Tuesday, June 3rd. Morgan Stanley set a $56.00 price objective on Sanofi in a research note on Monday, June 2nd. Finally, Barclays reiterated an "overweight" rating on shares of Sanofi in a research note on Wednesday, July 2nd. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $62.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.